CDXC Niagen Bioscience Inc.


$ 6.72 $ -0.28 (-4.07 %)    

Thursday, 06-Nov-2025 16:45:15 EST
QQQ $ 612.88 nm (nm)
DIA $ 469.80 $ -3.83 (-0.81 %)
SPY $ 671.66 nm (nm)
TLT $ 89.73 nm (nm)
GLD $ 365.78 $ -0.44 (-0.12 %)
$ 6.6
$ 7.29
$ 6.60 x 50
$ 6.73 x 1,000
$ 6.58 - $ 7.55
$ 5.16 - $ 14.69
1,761,717
na
na
$ 0.79
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chromadex-corp-changes-name-to-niagen-bioscience-ticker-symbol-changes-to-nage-on-march-19-2025

- SEC Filing

 hc-wainwright--co-reiterates-buy-on-chromadex-maintains-11-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:CDXC) with a Buy and maintains $11 price tar...

 hc-wainwright--co-maintains-buy-on-chromadex-raises-price-target-to-11

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target ...

 ladenburg-thalmann-maintains-buy-on-chromadex-raises-price-target-to-81

Ladenburg Thalmann analyst Jeffrey Cohen maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target from $6.8 ...

 chromadex-q4-2024-gaap-eps-009-beats-002-estimate-sales-29125m-beat-26733m-estimate

ChromaDex (NASDAQ:CDXC) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.02 by 35...

 chromadexs-pharmaceutical-grade-niagen-iv-now-accessible-at-over-200-restore-hyper-wellness-clinics-nationwide

National rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapyChromaDex Corp. (NAS...

 roth-mkm-maintains-buy-on-chromadex-raises-price-target-to-8

Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target from $6 to $8.

 hc-wainwright--co-maintains-buy-on-chromadex-raises-price-target-to-8

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION